EMBER

American Rare Earths Announces Breakthrough Metallurgical Results  

Retrieved on: 
Monday, January 22, 2024
Tetra, ASX, EMBER, Competent person, Tetra Tech, Society, University, Mining, ARR, LLNL, Southeast Asia, DARPA, Rare-earth element

DENVER, Jan. 22, 2024 (GLOBE NEWSWIRE) --  American Rare Earths (ASX: ARR | ADRs - OTCQX: AMRRY | Common Shares - OTCQB: ARRNF) (“ARR” or the “Company”) is pleased to announce breakthrough metallurgical results as part of the SynBREE project, a consortium led by Lawrence Livermore National Laboratory (LLNL) as part of a program funded by the Environmental Microbes as a BioEngineering Resource (EMBER) program within Defense Advanced Research Projects Agency (“DARPA”), a U.S. Department of Defense (DoD) agency.

Key Points: 
  • Preconcentrating reduces Wet High Intensity Magnetic Separator (“WHIMS”) needs by 70% from existing design, significantly reducing capital and operating expenditures.
  • The project has been selected to advance to the next phase of study and the company is engaged in discussions around funding and next steps.
  • DENVER, Jan. 22, 2024 (GLOBE NEWSWIRE) -- American Rare Earths (ASX: ARR | ADRs - OTCQX: AMRRY | Common Shares - OTCQB: ARRNF) (“ARR” or the “Company”) is pleased to announce breakthrough metallurgical results as part of the SynBREE project, a consortium led by Lawrence Livermore National Laboratory (LLNL) as part of a program funded by the Environmental Microbes as a BioEngineering Resource (EMBER) program within Defense Advanced Research Projects Agency (“DARPA”), a U.S. Department of Defense (DoD) agency .
  • Removal of the gangue materials at the solid state enhances the concentration of the rare earth elements, creating an optimal solution feed for downstream bio-separation.

Lilly Announces Details of Presentations at ESMO Congress 2023

Retrieved on: 
Friday, October 6, 2023
Congress, Selpercatinib, Eli Lilly and Company, ID, NYSE, NSCLC, RET, Risk, Adjuvant, MTC, Lilly, The Monarch School, Triple-negative breast cancer, Recurrence, Everolimus, CEST, Oncology, ESMO, LLY, EMBER, EBC, Transfection, ET, Vandetanib, European Society for Medical Oncology, Patient, Poster, Cabozantinib, Pharmaceutical industry, Vaccine

In a late-breaking oral presentation, Lilly will share five-year results, an established benchmark for adjuvant breast cancer trials, from a preplanned interim analysis of the Phase 3 monarchE study.

Key Points: 
  • In a late-breaking oral presentation, Lilly will share five-year results, an established benchmark for adjuvant breast cancer trials, from a preplanned interim analysis of the Phase 3 monarchE study.
  • A separate poster presentation will provide data on the impact of dose reductions on efficacy for patients treated in monarchE.
  • In two late-breaking oral presentations that will be featured as part of the Presidential Symposium 1 on Saturday, October 21, Lilly will share interim analysis results from the Phase 3 LIBRETTO-431 and LIBRETTO-531 clinical studies.
  • In a mini oral presentation, Lilly will share clinical data on imlunestrant as a single agent and in combination therapy.

Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Wednesday, November 30, 2022
MOA, NEO, HER2, Epitope, Recurrence, Chain reaction, SD, LLY, TSX, 2021 Essex County Council election, EMBER, Breast cancer classification, DNA, Poster, Radar, Circulating tumor DNA, Therapy, Health, MBA, Patient, Data, Polymerase, Eli Lilly and Company, Progression-free survival, Neoplasm, Fulvestrant, Tumor microenvironment, Eli Lilly, Research, Norwich Pharma Services, TNBC, US, PCR, ONC, G1 Therapeutics, NeoGenomics, NYSE, Oncolytics Biotech, The Monarch School, MRD, News, Woman, Breast cancer, Survival, ER, Paclitaxel, Pharmaceutical industry, Medical imaging, Vaccine, Abemaciclib, Trilaciclib

VANCOUVER, British Colombia, Nov. 30, 2022 /PRNewswire/ -- USA News Group  -  A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world. This year's SABCS is already shaping up to contain some big developments, including data and presentations from biotech companies such as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company (NYSE: LLY), NeoGenomics, Inc. (NASDAQ: NEO), Zymeworks Inc. (NYSE: ZYME), and G1 Therapeutics, Inc. (NASDAQ: GTHX).

Key Points: 
  • The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world .
  • The second poster will include data from a collaboration with SOLTI-Innovative Cancer Research from the AWARE-1 window-of-opportunity study in early-stage breast cancer patients.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.

Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Wednesday, November 30, 2022
MOA, NEO, HER2, Epitope, Recurrence, Chain reaction, SD, LLY, TSX, 2021 Essex County Council election, EMBER, Breast cancer classification, DNA, Poster, Radar, Circulating tumor DNA, Therapy, Health, MBA, Patient, Data, Polymerase, Eli Lilly and Company, Progression-free survival, Neoplasm, Fulvestrant, Tumor microenvironment, Eli Lilly, Research, Norwich Pharma Services, TNBC, US, PCR, ONC, G1 Therapeutics, NeoGenomics, NYSE, Oncolytics Biotech, The Monarch School, MRD, News, Woman, Breast cancer, Survival, ER, Paclitaxel, Pharmaceutical industry, Medical imaging, Vaccine, Abemaciclib, Trilaciclib

VANCOUVER, British Colombia , Nov. 30, 2022 /PRNewswire/ -- USA News Group  -  A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world. This year's SABCS is already shaping up to contain some big developments, including data and presentations from biotech companies such as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company (NYSE: LLY), NeoGenomics, Inc. (NASDAQ: NEO), Zymeworks Inc. (NYSE: ZYME), and G1 Therapeutics, Inc. (NASDAQ: GTHX).

Key Points: 
  • The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world .
  • The second poster will include data from a collaboration with SOLTI-Innovative Cancer Research from the AWARE-1 window-of-opportunity study in early-stage breast cancer patients.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.

Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Monday, November 21, 2022
The Monarch School, Adult, Cell death, Food and Drug Administration, PI3K, Growth, Cancer, EMBER, Cyclin D1, Recurrence, Plasma, Breast, Febrile neutropenia, PIK3CA, Rb, Woman, Cell proliferation, Diarrhea, SERD, Infection, ER, Tamoxifen, Traffic barrier, CDK, Physician, Cerebrospinal fluid, Eli Lilly and Company, FDA, Breast cancer, Breast cancer classification, Phosphorylation, ESR1, ET, EBC, NYSE, OS, S phase, Hospital, Pharmacology, Patient, Molecular biology, Grade 3, Apoptosis, Toxicity, Risk, Dehydration, Cyclin-dependent kinase, Loperamide, Lilly, Retinoblastoma protein, Food, Cell cycle, Preclinical development, Grade 2, Pharmaceutical industry, Birth control, Medical imaging, Abemaciclib, Neutropenia, G1

INDIANAPOLIS, Nov. 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)today announced that study investigators will present data from its breast cancer portfolio and pipeline at the 2022 San Antonio Breast Cancer Symposium (SABCS), to be held December 6-10, 2022, in San Antonio, Texas, and virtually.

Key Points: 
  • INDIANAPOLIS, Nov. 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)today announced that study investigators will present data from its breast cancer portfolio and pipeline at the 2022 San Antonio Breast Cancer Symposium (SABCS), to be held December 6-10, 2022, in San Antonio, Texas, and virtually.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.
  • In patients with advanced cancer, including breast cancer, concentrations of Verzenio and its active metabolites (M2 and M20) in cerebrospinal fluid are comparable to unbound plasma concentrations.

American Rare Earths Ltd Teams Up for Defense R&D: Rare Earths Processing

Retrieved on: 
Wednesday, June 29, 2022
Carbon, Broad Agency Announcement, Science and technology in Asia, OTCQB, Research, Yttrium, FSE, Maximal and minimal elements, Engineering, University of Kentucky, Lawrence Livermore National Laboratory, Pennsylvania State University, GLOBE, ASX, Columbia University, COVID-19, Element, EMBER, Company, Industry, JORC, Australian Securities Exchange, DARPA, Tufts University, Copper, Rare-earth element, Electric vehicle, Technology, Ceramic, WRE, Scandium, University, Gold, Private Securities Litigation Reform Act, Purdue University, LLNL, REE, Program, National security, Forward-looking statement, United States Department of Defense, TB

Feedstocks from the La Paz Rare Earth Project and Halleck Creek Rare Earth Project, both 100% Company owned, have been provided to researchers.

Key Points: 
  • Feedstocks from the La Paz Rare Earth Project and Halleck Creek Rare Earth Project, both 100% Company owned, have been provided to researchers.
  • Chris Gibbs, MD/CEO of American Rare Earths Limited, said, We are honored to have our US technical and management team collaborate with the leading researchers on cutting-edge technologies.
  • Rare Earths separation and purification would benefit from a new tech stack combined with traditional mineral processing approaches.
  • The consortium draws on a wealth of rare earths experience in processing, separation, purification, and economic analysis.

Enduring Hope: New Novel EMBER Explores How To Stay Resilient In A Supernatural World

Retrieved on: 
Friday, May 27, 2022
Loneliness, Fear, Hunger, Beauty, Rape, EMBER, Book, Trauma, Starvation, Pain, Frustration, Physical abuse, Life, Heart, Amber, Fantasy, Love, Male, Mark (given name), Davidson, GLOBE, Entertainment

So after years of frustration with the outcomes of books she had read, Audra M. Davidson decided to follow her passion and write her own fantasy.

Key Points: 
  • So after years of frustration with the outcomes of books she had read, Audra M. Davidson decided to follow her passion and write her own fantasy.
  • These are the questions at the heart of her debut fantasy novel.
  • In EMBER, the first book in the series, Amber is a young woman looking to start over.
  • Raised in Northwest Illinois, Audra M. Davidson works as a 911 dispatcher for her local police department.